(Q35150296)

6 August 2017

1 reference

title

Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis (English)

1 reference

6 August 2017

0 references

1 reference

Scott S Zamvil

1

1 reference

6 August 2017

Lawrence Steinman

series ordinal

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

38

1 reference

6 August 2017

issue

5

1 reference

6 August 2017

page(s)

685-688

1 reference

The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

Identification of autoantibodies associated with myelin damage in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

Myelin failure in multiple sclerosis: breaking the spell of Notch

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

Identification of Bphs, an autoimmune disease locus, as histamine receptor H1.

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

A controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination.

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

Experimental autoimmune encephalomyelitis mobilizes neural progenitors from the subventricular zone to undergo oligodendrogenesis in adult mice

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

Glutamate excitotoxicity in a model of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

Immunopathology of secondary-progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

Multiple sclerosis: a two-stage disease

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900326-X

7 January 2021

10.1016/S0896-6273(03)00326-X

Identifiers

DOI

1 reference

6 August 2017

1 reference